Label-free oxygen-metabolic photoacoustic microscopy in vivo by Yao, Junjie et al.
Label-free oxygen-metabolic
photoacoustic microscopy in vivo
Junjie Yao
Konstantin I. Maslov
Yu Zhang
Younan Xia
Lihong V. Wang
Downloaded From: http://biomedicaloptics.spiedigitallibrary.org/ on 07/01/2016 Terms of Use: http://spiedigitallibrary.org/ss/TermsOfUse.aspx
Journal of Biomedical Optics 16(7), 076003 (July 2011)
Label-free oxygen-metabolic photoacoustic
microscopy in vivo
Junjie Yao, Konstantin I. Maslov, Yu Zhang, Younan Xia, and Lihong V. Wang
Washington University in St. Louis, Department of Biomedical Engineering, One Brookings Drive,
St. Louis, Missouri 63130
Abstract. Almost all diseases, especially cancer and diabetes, manifest abnormal oxygen metabolism. Accurately
measuring the metabolic rate of oxygen (MRO2) can be helpful for fundamental pathophysiological studies, and
even early diagnosis and treatment of disease. Current techniques either lack high resolution or rely on exogenous
contrast. Here, we propose label-free metabolic photoacoustic microscopy (mPAM) with small vessel resolution to
noninvasively quantify MRO2 in vivo in absolute units. mPAM is the unique modality for simultaneously imaging
all five anatomical, chemical, and fluid-dynamic parameters required for such quantification: tissue volume, vessel
cross-section, concentration of hemoglobin, oxygen saturation of hemoglobin, and blood flow speed. Hyperther-
mia, cryotherapy, melanoma, and glioblastoma were longitudinally imaged in vivo. Counterintuitively, increased
MRO2 does not necessarily cause hypoxia or increase oxygen extraction. In fact, early-stage cancer was found to
be hyperoxic despite hypermetabolism. C©2011 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.3594786]
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1 Introduction
The energy demand of mammals is primarily met by aerobic
metabolism, producing 88% of ATP molecules.1 Therefore, the
metabolic rate of oxygen (MRO2) is an important indicator of
tissue viability and functionality. It is known that nearly all
cancers after the early stage are starved for oxygen (hypoxia)
due to hypermetabolism and/or limited blood supply, regard-
less of their cellar origins.2 In the presence of low oxygen
pressure, highly malignant cancer cells survive and prolifer-
ate via glycolysis (anaerobic respiration, the Warburg effect).
The presence of a large number of hypoxic regions within a
tumor usually correlates with a poor prognosis.1 This metabolic
phenotype has become the basis for tumor imaging by positron
emission tomography (PET) using radioactively labeled oxy-
gen. Many other pathological and physiological functions are
also closely related to alterations of oxygen metabolism: ex-
amples include Alzheimer’s disease,3 diabetes,4 burns,5 ob-
structive pulmonary disease,6 congestive heart failure,7 aging,8
sleeping,9 and physiologic challenges.10 Therefore, an accu-
rate measurement of MRO2 has the potential to provide a
powerful tool for diagnosis and therapy of cancer and other
diseases as well as for metabolism-related pathophysiological
studies.
Compared with other oxygenation indexes of tissue, i.e.,
oxygen saturation (sO2) of hemoglobin and partial oxygen
pressure (pO2), MRO2 is superior because it directly reflects
the rate of oxygen consumption instead of the static oxygen
concentration.11 If the region of interest has well-defined feed-
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ing and draining vessels, we have12
MRO2 = ε×CHb× (sO2in×Ain×v¯in − sO2out×Aout×v¯out )/W.
(1)
Here, subscripts in and out denote feeding and draining
vessels, respectively. ε is the oxygen binding capacity of
hemoglobin and is usually taken as a constant (1.36 ml O2/gram
hemoglobin).13 CHb is the total hemoglobin concentration (in
grams of hemoglobin/ml blood). sO2 is the average oxygen sat-
uration (in %). A is the cross-sectional area (in mm2). v¯ is the
average blood flow speed (in mm/s). W is the weight of the
region of interest (in grams). While CHb can be estimated any-
where in the trunk vasculature, the other parameters must be
locally measured.
Presently, three primary imaging modalities are used to quan-
tify MRO2.12 Among them, PET is most widely used in clin-
ical practice. However, the need for injection or inhalation
of radioactively labeled exogenous tracers results in a com-
plex procedure with exposure to ionizing radiation, limiting its
usage.14 Functional magnetic resonance imaging (fMRI) has
also been intensively used for MRO2 study, especially in the
brain. fMRI is limited to qualitative evaluation of only tem-
poral changes in MRO2 and has difficulty in measuring both
CHb and sO2.15 It also must switch between different imag-
ing protocols to measure sO2 and v¯ .16, 17 Moreover, both PET
and fMRI are expensive. Diffuse optical tomography (DOT)
is also capable of measuring MRO2 and is relatively inexpen-
sive, but it relies on an approximate theoretical model or other
techniques (e.g., Doppler ultrasound and laser Doppler) to pro-
vide blood flow information.18, 19 Recently, DOT has been com-
bined with diffuse correlation spectroscopy (DCS), which is
capable of providing relative blood flow information.20 Fur-
thermore, due to their relatively poor spatial resolutions, PET,
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fMRI, and DOT usually measure MRO2 averaged over a large
volume.21
Here, we overcome these limitations by developing label-
free metabolic photoacoustic microscopy (mPAM) that ultra-
sonically measures optical contrast through the photoacoustic
(PA) effect. For the first time, we demonstrated that all five
anatomic, chemical, and fluid-dynamic parameters for MRO2
quantification can be obtained in absolute units by mPAM alone
in vivo. To validate mPAM, first we studied the MRO2 responses
to hyperthermia and cryotherapy, two common therapeutic tech-
niques. Furthermore, mPAM was used to longitudinally im-
age melanoma and glioblastoma, demonstrating its capability of
early cancer detection.
2 Materials and Methods
2.1 Ethical Review of Procedures
All experimental animal procedures were carried out in confor-
mity with the laboratory animal protocol approved by the Animal
Studies Committee at Washington University in St. Louis.
2.2 Experimental Animals
The ears of adult, four- to five-week-old nude mice (Hsd:
Athymic Nude-FoxlNU, Harlan Co.; body weight: ∼20 g) were
used for all in vivo experiments. During data acquisition, the
animal was held steady with a dental/hard palate fixture and
kept still by using a breathing anesthesia system (E-Z Anes-
thesia, Euthanex). After the experiment, the animal naturally
recovered and was returned to its cage. For tumor study, af-
ter monitoring, the animal was sacrificed by an intraperitoneal
administration of pentobarbital at a dosage of 120 mg/kg.
2.3 Metabolic Photoacoustic Microscopy
Metabolic photoacoustic microscopy [Fig. 1(a)] is based on
newly developed photoacoustic microscopy, which has shown
a robust capability to noninvasively image microvasculature us-
ing endogenous contrast with high spatial resolution (lateral:
∼5 μm; axial: ∼15 μm).22 Briefly speaking, a tunable dye
laser (CBR-D, Sirah) pumped by a Nd:YLF laser (INNOSAB,
Edgewave, 523 nm) serves as the light source. The laser pulse
is reshaped by a 25-μm diameter pinhole and focused onto
the surface of the mouse ear by a microscope objective lens
(Olympus 4×, NA = 0.1) with a pulse energy of ∼100 nJ.
Ultrasonic detection is achieved through a spherically focused
ultrasonic transducer (V2012-BC, Panametrics-NDT), which is
confocally placed with the objective. The detected PA signal is
then amplified, digitized, and saved. A volumetric image is gen-
erated by recording the time-resolved PA signal (A-line) at each
horizontal location of the two-dimensional raster scan. The mo-
tion controller provides the trigger signals for laser firing, data
acquisition, and motor scanning.
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Fig. 1 Label-free quantification of MRO2 in vivo. (a) Schematic of mPAM system. Nanosecond laser pulses pass through a pinhole and are focused
on the animal’s skin surface by an objective. The resultant PA signal is detected by a focused ultrasonic transducer, which is confocally placed with
the objective. A transverse resolution of 5 μm and an axial resolution of 15 μm are achieved, with a penetration depth greater than 700 μm. CL:
correction lens; AL: acoustic lens; SQL: silicone oil layer; UT: ultrasonic transducer; WT: water tank; MS: motorized scanner. (b) mPAM image of the
total concentration of hemoglobin (CHb). Scale bar: 500 μm. (c) mPAM image of the sO2 of hemoglobin in the area indicated by the dashed box in
(b). Scale bar: 125 μm. (d) mPAM image of blood flow in the area indicated by the dashed box in (c). Red arrow: positive scanning direction; blue
arrow: negative scanning direction. Positive velocity: upward flow. Scale bar: 125 μm. (e) Profile of blood flow speed across the dashed line in (d).
(Color online only.)
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All of the parameters for MRO2 quantification in Eq. (1) can
be simultaneously obtained by mPAM. Specifically, anatomic
parameters W and A are quantified from the structural mPAM
image;23 functional parameters CHb and sO2 are measured
by laser excitation at two wavelengths;23, 24 fluid-dynamic pa-
rameter v¯ is estimated on the basis of photoacoustic Doppler
bandwidth broadening of the PA signal induced by circulating
red blood cells.25, 26 The structural image acquisition time is
∼25 min for a 4 mm × 4 mm region (∼1 Hz frame rate)
using a single wavelength; the oxygenation image acquisition
time is ∼20 min for a 1 mm × 1 mm region using two wave-
lengths (∼0.3 Hz frame rate); the flow speed acquisition time
is ∼5 min for a 0.5 mm cross-sectional line using a single
wavelength.
2.4 Hyperthermia Experimental Protocol
In the hyperthermia study, the animal’s temperature was reg-
ulated by adjusting the water temperature in the heating pad
placed underneath its abdomen. The water was circulated by a
water-bath system (ISOTEMP 9100, Fisher Scientific). A cot-
ton layer between the heating pad and the animal skin buffered
and homogenized the temperature change and thus protected
the animal from burns. The room temperature was kept at 23 oC.
The animal’s skin temperature (SKT) was monitored on the dor-
sal pelvis by an attached electronic thermometer (Radio Shack,
Cat. No. 63-854). Before the experiment, the SKT was adjusted
to 31 oC, which was used as the baseline. The experiment was
divided into three periods. The animal was first monitored at
baseline temperature for ∼40 min (the resting period), then
heated for ∼30 min by increasing the heading pad to 50 oC
(the heating period), and last allowed to cool to baseline for
∼100 min (the recovery period). The hemodynamic parameters
were simultaneously measured on the principal artery-vein pair
(AVP) using mPAM. Each measurement took ∼6 min and the
whole experiment lasted for ∼3 h.
2.5 Tumor Cell Culture
B16 mouse melanoma cells were obtained from the Tissue
Culture and Support Center at the Washington University
School of Medicine. The cells were maintained in Dulbecco’s
modified Eagle medium (DMEM, Invitrogen, Carlsbad, Cali-
fornia) supplemented with 10% fetal bovine serum (FBS) and
1% P/S. U87 MG human brain glioblastoma cells (HTB-14)
were obtained from American Type Cell Culture (ATCC). The
cells were maintained in Eagle’s Minimum Essential Medium
(EMEM, Invitrogen) supplemented with 10% heat-inactivated
FBS (ATCC) and 1% penicillin-streptavidin (P/S, Invitrogen).
The cultures were performed at 37 ◦C and 5% CO2 and the cells
were passaged weekly.
2.6 Inoculation of Tumor Cells
In the tumor study, 0.01 ml of suspension containing ∼0.5 mil-
lion B16 melanoma cells or U87 human glioblastoma cells was
inoculated into the top skin layer in the left ear of a nude
mouse, using a 0.3 ml syringe with a 29-gauge needle. The
injection was usually located near the second order branch of
the principal AVP above the cartilage. The tumor was allowed
to grow and monitored for one to three weeks. A control mea-
surement was performed before the tumor cell injection (day
zero).
2.7 Hemodynamics Measured by Metabolic
Photoacoustic Microscopy
The hemodynamic parameters were monitored using mPAM
on the principal AVP, which included vessel diameter, total
hemoglobin concentration, oxygen saturation, blood flow di-
rection, and flow speed.
1. Vessel diameter. The vessel diameter was measured
along a cross-section perpendicular to the vessel cen-
terline. A threshold of two times the noise level was
empirically set to separate the background and vessel.
The transverse dimension of the vessel cross section was
taken as the vessel diameter D, in case the excitation
light could not penetrate the whole vessel in the axial
direction. Then the vessel cross-section area was calcu-
lated as A = π (D/4)2. Five adjacent cross sections were
measured and the mean value of the principal vein was
used for MRO2 calculation.
2. Total hemoglobin concentration. Since oxy- and deoxy-
hemoglobin have the same absorption coefficient at
584 nm, the PA signal amplitude is proportional to the
total hemoglobin concentration regardless of the oxygen
saturation level.27 On the basis of a previous study,28 the
total hemoglobin concentration was set to be 146.0 g/l
at baseline temperature (the hyperthermia study) and
on day zero (the tumor and cryotherapy studies). The
sequential data sets were accordingly calibrated. The av-
eraged PA signal amplitude along the centerline of the
principal vein was used for calculation.
3. Oxygen saturation. The sO2 was measured using laser
excitations at 584 and 590 nm, respectively.24 The rela-
tive change in molar extinction coefficient is ∼58.4%
for oxy- and 17.5% for deoxy-hemoglobin, respec-
tively. Because the vessels studied here were big enough
(> 50 μm) and the laser pulse energy was low (∼100 nJ),
the difference of penetration depth will not affect the
results much. The PA signal at each wavelength was
normalized with the laser pulse energy, as monitored by
a wavelength-calibrated photodiode. The averaged sO2
along the vessel centerline was used for the MRO2 cal-
culation. The PA image acquired at 584 nm was used
as a mask on the sO2 image to remove the background
noise.
4. Blood flow direction. The blood flow direction was
measured on the basis of photoacoustic Doppler band-
width broadening with bidirectional motor scanning at
584 nm.25 The laser repetition rate was 3 KHz and the
scanning step size was 0.625 μm. We used 64 sequen-
tial A-lines to calculate the bandwidth broadening. If
the blood flow had a positive projection along the posi-
tive scanning direction, we defined it as a positive flow
and vice versa. The mPAM image acquired at 584 nm
was used as a mask on the flow image to remove the
background noise.
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5. Blood flow speed. To better estimate the flow speed,
M-mode imaging at 584 nm was used to measure the
bandwidth broadening across the vessel. The laser repe-
tition rate was 3 KHz and 3200 A-lines were acquired at
each position. The flow speed at each position was calcu-
lated on the basis of the Doppler bandwidth broadening.
The average amplitude of the PA signal at each position
was used as a mask on the speed profile to remove the
background noise. The mean flow speed of the principal
vein was used for MRO2 calculation.
2.8 Melanoma Volume Estimation using Metabolic
Photoacoustic Microscopy
After data acquisition, the PA signal amplitude acquired at
each optical wavelength was extracted through the Hilbert
transformation. The tumor region was then separated from
the surrounding blood vessels according to the mPAM image
acquired at 605 nm, where melanin has much stronger absorp-
tion than blood. A threshold of 20% of the maximum signal
amplitude was set to segment the tumor. Since it was challenging
to penetrate through the whole tumor due to the high absorption
of melanin, a 3D envelope of the tumor region was obtained from
the surface signal instead. The volume of the tumor was then cal-
culated by integrating the corresponding voxels enclosed by the
envelope. All of the image processing was conducted using the
MATLAB Image Processing Toolbox (R2008a, MathWorks).
2.9 Fitting for the Proﬁle of Blood Flow Speed
A theoretical model was used to fit the profile of the blood flow
speed across the vessel,29
v(x) = vmax×
[
1 −
(
x − x0
R
)n]
. (2)
Here, x is the transverse location, x0 is the vessel center, R is
the vessel radius, vmax is the flow speed at the vessel center, and
n is the power index that characterizes the flow profile (e.g., n
= 2 for laminar flow). While x0 and R can be directly measured
from the mPAM images of the vessel structure, vmax and n are
the unknown parameters to fit for.
2.10 Statistical Analysis
Quantitative data was expressed as mean ± s.e.m. The statis-
tical test is a paired Student’s t-test (two-tailed with unequal
variance), compared with the baseline levels (hyperthermia and
cryotherapy studies) or day zero (tumor studies). We considered
a p-value less than 0.05 to be statistically significant.
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Fig. 2 mPAM measurements of sO2 and blood flow on four orders of artery-vein pairs in the mouse ear. (a) sO2 mapping from two measurements at
584 and 590 nm. Four different orders of artery-vein pairs are labeled. Scale bar: 125 μm. (b) Profiles of blood flow speed across vessels of different
orders measured along the dashed lines in (a) on the basis of PA Doppler bandwidth broadening at 584 nm. Generally, the flow speed decreases
from the proximal order to the distal order. However, it also depends on the vessel diameter as a result of the conservation of total flow. Solid circles:
experimental data; red curves: fit. (c) Mean sO2 versus the vessel order, quantified along the centerline of each vessel. The sO2 values in both the
arteries and veins slightly change with the vessel order, especially at distal branches. This is probably due to oxygen diffusion between the arteries
and veins, and the inhomogeneous MRO2. (d) Blood flow rate (in μl/min) versus the vessel order, quantified from the flow speed profiles and vessel
diameters. Blood flow in both arteries and veins decreases from the proximal order to the distal order and is conserved between the artery and vein
of the same order. The blood fed by the artery is mostly drained by the corresponding vein of the same order. V: vein; A: artery. (Color online only.)
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3 Results
3.1 Metabolic Rate of Oxygen Quantiﬁcation
under Normothermia
The nude mouse ear is a good model for validating mPAM
because of its similarity to human skin and lack of motion
artifacts.30–32 Each artery-vein pair (AVP) feeds a well-defined
region while one pair at the base of the ear feeds the entire
ear (Fig. 2).33, 34 Consequently, the MRO2 based on each AVP
approximates the MRO2 of its supplied region.
As an example, we measured the MRO2 of a mouse ear
under normothermia. The animal’s temperature was regulated
with a heating pad placed under its abdomen (skin temperature:
31 oC) and a volumetric image was acquired using mPAM at
584 nm by scanning a 10 mm × 8 mm area containing the prin-
cipal AVP [Fig. 1(b)]. Because 584 nm is an isosbestic wave-
length for hemoglobin, this image maps the concentration of
total hemoglobin regardless of the oxygen saturation level. In
addition, it measures the diameters of the principal AVP (artery:
∼65 μm; vein: ∼116 μm). Two PAM images acquired at 584
and 590 nm were then used to calculate sO2 [Fig. 1(c)].23 The
vessels with high sO2 values (>90%) are classified as arter-
ies, whereas the vessels with low sO2 values (60 to 80%) are
veins. The blood flow velocity was measured at 584 nm using
bi-directional scanning with a laser repetition rate of 3 KHz and
a motor step size of 0.625 μm [Fig. 1(d)]. The profile of flow
speed across the principal AVP is shown in Fig. 1(e). The artery
and the vein have a mean flow speed of 5.5 and 1.8 mm/s, respec-
tively, and the speed profiles are both approximately parabolic.29
The weight of the mouse ear was computed by its volume in the
3D PA image, where the average specific weight was assumed
to be 1.0 g/ml.35 From these measurements, the MRO2 of the
mouse ear was estimated to be 0.23 ml/100 g/min, which agrees
with the data previously measured in humans.2
3.2 Change in Metabolic Rate of Oxygen Induced
by Systemic Hyperthermia
Hyperthermia has been clinically used for cancer treatment.36
To measure MRO2 during hyperthermia, the mouse’s skin tem-
perature was elevated to 42 oC [Fig. 3(a)]. Hemodynamics were
monitored on the principal of AVP. The vessel diameter started
increasing at the beginning of the heating period [Fig. 3(b)]
and reached a maximum by the end of the heating period. The
total hemoglobin concentration of the principal AVP kept in-
creasing after the heating started and plateaued when the tem-
perature returned to the baseline [Fig. 3(c)]. This cumulative
effect was due to a decrease in blood plasma volume resulting
from water loss during hyperthermia.37 From the change in sO2
[Fig. 3(d)], we found that the oxygen extraction fraction (OEF,
defined as (sO2in − sO2out )/sO2in and represents the fraction of
O2 molecules that cross the capillary wall) decreased by 12%
over the heating period and eventually recovered to 99% of the
resting level [Fig. 3(f)]. The measurements of flow speed in the
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(MRO2). (Color online only.)
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Fig. 6 mPAM characterization of melanoma progression. mPAM measurements in absolute units of (a) ear weight, (b) vessel diameter, (c) total
hemoglobin concentration, (d) sO2 of hemoglobin, (e) volumetric blood flow rate, (f) OEF, (g) rate of O2 consumption in μl/min, and (h) MRO2
in ml/100 g/min up to 21 days after tumor inoculation. Statistics: paired Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001, n = 3. Data are
presented as means ± s.e.m.
arteries during the heating were saturated because of the limited
maximum measurable speed of the system [Fig. 3(e)]. From the
measurements on the principal veins, we found the volumetric
flow rate of blood entering the ear increased by 45%. Increased
cardiac output and redistribution of blood to the skin are two
major reasons for vessel dilation and faster blood flow, which
help accelerate heat exchange with the environment.36, 38 Note
that the vessel diameter, sO2, and blood flow speed reach the
peaks approximately simultaneously.
The MRO2 of the mouse ear, as computed from the hemo-
dynamic changes, increased by 28% over the heating period
[Fig. 3(f)], which indicated elevated oxygen metabolism dur-
ing hyperthermia in response to an increased rate of enzymatic
reactions.39 This finding can potentially elucidate another pos-
sible mechanism for cell death induced by hyperthermia. When
normal cells encounter such an increased metabolism, increased
blood flow provides more nutrients. By contrast, cancer cells
could be damaged owing to inadequate blood circulation. There-
fore, hyperthermia may kill cancer cells by both protein denat-
uration and cell starvation due to heating.
3.3 Change in Metabolic Rate of Oxygen Induced
by Local Cryotherapy
Cryotherapy has been found effective for treating cancer and
other diseases by forming ice crystals inside cells.40, 41 Here, we
applied liquid nitrogen to the mouse ear surface for 10 s via a
1-mm diameter cryo-probe and monitored the hemodynamics of
the treated area [Figs. 4(a) and 4(b)]. An untreated neighboring
area of the same ear was also monitored as a control. Right after
the treatment, a global reflective vasodilatation was observed on
both the treated and control areas, which was accompanied by an
increase in blood flow and a decrease in OEF. While the MRO2
Day 0 Day 3
(a) (b)Photo mPAM
MT
Day 0
Day 3
C (g/l)0 150 0 350C (g/l)
Fig. 7 mPAM differentiation of blood vessels and melanoma. (a)
White-light photographs of a representative mouse ear before and
three days after the xenotransplantation of B16 melanoma cells. Scale
bar: 1 mm. (b) Composite mPAM images of blood vessels (in red)
and melanoma (in brown). The two are differentiated by using dual-
wavelength excitation at 584 and 605 nm. CHb: total hemoglobin
concentration. CM: melanin concentration. Scale bar: 250 μm. MT:
melanoma tumor. (Color online only.)
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(a) (b)
MT
0.50
Fig. 8 Histological validation of melanoma detection. (a) mPAM im-
age of a mouse ear bearing a B16 melanoma tumor acquired on day
seven. z is coded by colors: blue (superficial) to red (deep). Scale bar:
300 μm. (b) Images of H&E stained tissue slices cut approximately
across the tumor area (top) and nontumor area (bottom). Scale bar:
150 μm. MT: melanoma tumor. (Color online only.)
of the control area remained statistically unchanged, the MRO2
of the treated area decreased by 56% due to the induced cell
death. Therefore, mPAM can be used to evaluate the efficacy of
cryotherapy. Within one month after the treatment, while all of
the parameters of the control area monotonically recovered to the
baseline, the physiological progress of the treated area occurred
in phases [Fig. 4(c)]. Within three days following the reflective
vasodilatation, blood flow and OEF trended toward the baseline,
but MRO2 remained at a low level due to cell necrosis. Starting
from day five, inflammation was clearly observed, which was
triggered by the immune system and was helpful for both dead
cell clearance and new cell growth. Although the OEF continued
to decrease due to the increased flow speed,11 the MRO2 of
the treated area eventually returned to the baseline, reflecting
improved tissue viability. One month later, the inflammation
nearly ended and all of the parameters had recovered almost to
the baseline.
This study shows that each physiological phase after
cryotherapy imparts its signature on the local MRO2. The
common belief is that inflammation triggered by the immune
response further helps kill tumor cells.42 However, our results
show that the increased blood flow rate during inflammation
may assist the survival of residual tumor cells by providing
more nutrients and thus recovering the MRO2 level.
3.4 Early Cancer Detection by Measuring
Tumor-induced Change in Metabolic Rate
of Oxygen
The third demonstration of mPAM is early cancer detection by
measuring MRO2. The hemodynamics of the mouse ear were
longitudinally monitored after the injection of B16 melanoma
cells [Fig. 5(a)]. On day 7, vessel dilation appeared around
the tumor site as shown in Figs. 5(b) and 6(b). The volumetric
blood flow rate increased by 1.5 fold [Figs. 5(c) and 6(e)]. These
changes are important to ensure the supply of oxygen and nutri-
ents to the rapidly growing tumor and to provide routes for tumor
cell metastasis.43 The overall OEF of the tumor region decreased
by 43% [Figs. 5(c) and 6(f)] due to the increased blood flow.11
The vasculature and melanoma were differentiated according to
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Fig. 9 mPAM detection of early-stage glioblastoma by measuring MRO2. (a) White-light photographs of a representative mouse ear before (day
zero) and seven days after the xenotransplantation of U87 glioblastoma tumor cells. Scale bar: 2 mm. (b) mPAM images of microvasculature in the
tumor region [dashed boxes in (a)] at 584 nm. z is coded by colors: blue (superficial) to red (deep). Scale bar: 250 μm. (c) mPAM images of sO2
in the artery-vein pair [double arrows in (b)] that supports the tumor region acquired on day zero and day seven. Scale bar: 100 μm. (d) mPAM
quantification of volumetric blood flow rate, OEF and MRO2 seven days after the tumor xenotransplantation, normalized by the values of day zero
(flow rate: 1.03 ± 0.41 μl/min; OEF: 0.27 ± 0.03; MRO2: 0.31 ± 0.09 ml/100 g/min). (e) Comparison of the averaged sO2 values in the intra- and
extra-tumoral vasculatures. Statistics: paired Student’s t-test. * p < 0.05, ** p < 0.01, n = 5. Data are presented as means ± s.e.m. GT: glioblastoma
tumor. (Color online only.)
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Fig. 10 Histological validation of glioblastoma detection. (a) mPAM image of a mouse ear bearing a U87 glioblastoma tumor acquired on day
seven. z is coded by colors: blue (superficial) to red (deep). Scale bar: 250 μm. (b) Images of H&E stained tissue slices cut approximately across the
tumor (left) and nontumor areas (right). Scale bar: 150 μm. GT: glioblastoma tumor. (Color online only.)
their different absorption spectra using dual-wavelength excita-
tion at 584 and 605 nm, and thus the tumor volume could be
estimated (Fig. 7). The hypermetabolism of melanoma was re-
flected by a 36% increase in MRO2 [Fig. 5(c)], which proves the
early cancer detection capability of mPAM. The presence of the
melanoma was confirmed by histology (Fig. 8). However, the
melanoma was hyperoxic instead of hypoxic in the early stage
[Fig. 6(d)]. On day 14, MRO2 dropped to the baseline level and
continued to decrease [Fig. 6(h)], even though the total oxygen
consumption rate steadily increased [Fig. 6(g)]. There are two
possible reasons for the final decline in MRO2. On one hand, a
tumor changes to anaerobic respiration instead of aerobic respi-
ration when it grows too quickly to get sufficient oxygen;2 on the
other hand, when the tumor grows too large, the tumor core dies
due to a decrease in available nutrients (necrosis). The necrotic
tumor core does not consume oxygen but increases tumor weight
[Fig. 6(a)], which decreases the MRO2.44
Besides melanoma, we also studied U87 human glioblastoma
[Fig. 9(a)], which is more transparent; thus, its intratumoral vas-
culature can be better visualized. On day seven, angiogenesis
was observed within the tumor region [Fig. 9(b)], and the sO2
of the draining vein was found to be increased, indirectly indi-
cating early-stage tumor hyperoxia [Fig. 9(c)]. The presence of
the glioblastoma was confirmed by histology (Fig. 10). While
the increase in blood supply for the glioblastoma was compara-
ble with that for the melanoma, the OEF showed a decrease by
24% instead of 43% [Fig. 9(d)]. We observed a 100% increase
in MRO2 instead of 36% for the melanoma, which indicated
a stronger hypermetabolism at the early stage of glioblastoma.
However, characteristic of early-stage cancer,45 such hyperme-
tabolism did not lead to tumor hypoxia. In fact, the sO2 in the
intratumoral vasculature was even higher than that of the sur-
rounding normal tissue, directly indicating early-stage tumor
hyperoxia [Fig. 9(e)]. The increase in sO2 actually caused the
decrease in OEF in the tumor. This observation suggests that a
hypoxia-based diagnosis may not apply to early-stage cancer.46
4 Conclusions and Discussion
The observations presented here demonstrate the power of
mPAM as the only noninvasive label-free imaging modality that
can measure all of the parameters required for the quantification
of MRO2 in absolute units. Whereas MRO2 is the ultimate mea-
sure of oxygen metabolism, OEF and sO2 can be misleading
partial measures. Unlike as is commonly believed, a decrease
in OEF or an increase in sO2 does not necessarily indicate a
decrease in MRO2. Strikingly, we found early-stage cancer to
be hyperoxic instead of hypoxic despite the hypermetabolism.
mPAM can noninvasively measure anatomical, functional,
and fluid-dynamic information at the resolution of small ves-
sels, making it possible for MRO2 quantification in microenvi-
ronments. MRO2-based early cancer detection and evaluation
of its treatment are highly desirable. mPAM also has various
other prospective applications related to MRO2. First, its high
spatial resolution is essential for micro-hemodynamic studies,
such as monitoring of local hemorrhage caused by mini-strokes.
Second, its high sensitivity is critical for studies concerning
small metabolic changes, such as the monitoring of neuro-
vascular coupling in response to physiological challenges. Third,
its potentially real-time imaging through fast optical scanning
or ultrasonic-array detection is important for studies involving
short transition times between physiological states, e.g., mon-
itoring of epileptic seizures. Finally, its high spatial scalabil-
ity enables us to correlate microscopic and macroscopic studies
(e.g., monitoring of local neuron firing and overall brain activity)
based on the same contrast. Overall, mPAM has strong poten-
tial for the study of metabolism in cancer and other metabolic
diseases.
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